Heredofamilial Amyloidosis Due to Transthyretin (hATTR): Cost Analysis From the Perspective of the Public Health Sector in Mexico
Author(s)
Laura J. Peralta, BSMA1, Victor E. Martinez, M.Econ.S.1, Erick Jael Palomo Paz, BSc1, Herman Soto, Sr., MSc1, Bertha E. Mancilla, MHE2, FERNANDO KARAM VARGAS, MBA2;
1HS ESTUDIOS FARMACOECONOMICOS, MEXICO CITY, Mexico, 2PTC THERAPEUTICS, MEXICO CITY, Mexico
1HS ESTUDIOS FARMACOECONOMICOS, MEXICO CITY, Mexico, 2PTC THERAPEUTICS, MEXICO CITY, Mexico
OBJECTIVES: To estimate the costs associated with the treatment of Hereditary Transthyretin Amyloidosis (hATTR) in adult patients from the perspective of the public health sector in Mexico.
METHODS: The microcosting methodology was used to estimate direct medical costs (monitoring, hospitalization, and complications) according to the Coutinho stage at diagnosis. A panel of seven experts: 4 neurologists, 2 cardiologists, and 1 gastroenterologist, all of them from public health institutions provided information on resource utilization. The unit costs used were obtained from reference portals of public health institutions in Mexico as of 2024. The final result consisted of estimating the total annual cost per patient, expressed in US dollars (USD) ($18.32 MxN to 1 USD).
RESULTS: The estimated total annual cost was $16,253.29, $61,968.90, and $194,095.04 for stages 1, 2, and 3 of the disease, respectively. In stages 2 and 3, the main cost components are related to complications (e.g. renal failure, cardiac arrhythmias, Cardiac insufficiency, neuropathic pain, Carpal tunnel syndrome) and hospitalization (intensive care unit, emergencies, and floor) representing approximately 94% in stage 2 and 98.6% in stage 3. On the other hand, in stage 1, complications (77.7%) and patient monitoring (17.9%) stand out as the primary costs.
CONCLUSIONS: The costs associated with complications dominate at all stages, suggesting that they represent a critical area for intervention to contain overall costs. The results highlight the potentially preventable economic burden if strategies for early diagnosis, effective monitoring, and preventing complications are implemented.
METHODS: The microcosting methodology was used to estimate direct medical costs (monitoring, hospitalization, and complications) according to the Coutinho stage at diagnosis. A panel of seven experts: 4 neurologists, 2 cardiologists, and 1 gastroenterologist, all of them from public health institutions provided information on resource utilization. The unit costs used were obtained from reference portals of public health institutions in Mexico as of 2024. The final result consisted of estimating the total annual cost per patient, expressed in US dollars (USD) ($18.32 MxN to 1 USD).
RESULTS: The estimated total annual cost was $16,253.29, $61,968.90, and $194,095.04 for stages 1, 2, and 3 of the disease, respectively. In stages 2 and 3, the main cost components are related to complications (e.g. renal failure, cardiac arrhythmias, Cardiac insufficiency, neuropathic pain, Carpal tunnel syndrome) and hospitalization (intensive care unit, emergencies, and floor) representing approximately 94% in stage 2 and 98.6% in stage 3. On the other hand, in stage 1, complications (77.7%) and patient monitoring (17.9%) stand out as the primary costs.
CONCLUSIONS: The costs associated with complications dominate at all stages, suggesting that they represent a critical area for intervention to contain overall costs. The results highlight the potentially preventable economic burden if strategies for early diagnosis, effective monitoring, and preventing complications are implemented.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE60
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Neurological Disorders, SDC: Rare & Orphan Diseases